April 12, 2025 a 08:00 am
IDXX: Fundamental Ratio Analysis - IDEXX Laboratories, Inc.
IDEXX Laboratories, Inc. shows noteworthy strength in its diagnostic and health-monitoring product portfolio for veterinary, livestock, and water testing markets. The company presents a stable investment opportunity with a promising outlook, backed by a sound fundamentals profile, making it a compelling consideration for long-term investors.
Fundamental Rating
The company's fundamentals reflect a solid performance in key financial metrics, though there is room for improvement in certain areas.
| Category | Score | Score Bar |
|---|---|---|
| Overall | 3 | |
| Discounted Cash Flow | 3 | |
| Return on Equity | 5 | |
| Return on Assets | 5 | |
| Debt to Equity | 1 | |
| Price to Earnings | 1 | |
| Price to Book | 1 |
Historical Rating
A comparison of current versus past metrics suggests a steady performance trend, offering insights into the company's financial consistency.
| Date | Overall | DCF | ROE | ROA | Debt/Equity | P/E | P/B |
|---|---|---|---|---|---|---|---|
| 2025-04-11 | 3 | 3 | 5 | 5 | 1 | 1 | 1 |
| N/A | 0 | 3 | 5 | 5 | 1 | 1 | 1 |
Analyst Price Targets
IDEXX Laboratories, Inc. displays optimistic analyst projections with a high target of $600, reflecting growth potential.
| High | Low | Median | Consensus |
|---|---|---|---|
| $600 | $247 | $536.5 | $479.75 |
Analyst Sentiment
Analyst sentiment remains positive, with a majority categorizing the stock as a buy, underscoring confidence in its market position.
| Rating | Count | Distribution |
|---|---|---|
| Strong Buy | 0 | |
| Buy | 10 | |
| Hold | 8 | |
| Sell | 1 | |
| Strong Sell | 0 |
Conclusion
IDEXX Laboratories, Inc. stands out as a strong player in the diagnostic market, with robust financial fundamentals and positive analyst sentiment. While its price-to-earnings and debt levels suggest caution, the company shows admirable growth potential, as hinted by analyst price targets. Investors may find the long-term prospects enticing given the market demand for veterinaries and diagnostic innovations. An overall ‘Buy’ consensus reflects optimism but demands investors to stay vigilant of industry and economic shifts.